Craig J. Thomas, Ph.D.

Senior Scientist

Precision Therapeutics & Translational Technologies (PT3)

NCATS

View Site

9800 Medical Center Drive
Building A, Room 241A
Rockville, MD 20850

301-827-1798

craigt@mail.nih.gov

Research Topics

Our team utilizes state of the art methods in disease model development/characterization, high-throughput screening, medicinal chemistry/chemical biology, and therapeutic development to pursue a wide range of research goals. We pursue several domains of research 1) small molecule discovery, 2) drug repositioning and drug combination discovery and 3) precision medicine.

Biography

Craig Thomas received his B.S. from the University of Indianapolis in 1995 and received his Ph. D. from Syracuse University in 2000. Dr. Thomas was an American Cancer Society post-doctoral studies at the University of Virginia. Dr. Thomas moved to the NIH 2003 with positions at NIDDK, NHGRI and is currently a team leader in the Division of Preclinical Innovation at the National Center for Advancing Translational Sciences (NCATS) and as an adjunct Investigator in the Lymphoid Malignancies Branch at the National Cancer Institute (NCI). He serves on the editorial boards of Scientific Data and ACS Pharmacology and Translational Sciences and is a lecturer for the NIH’s Principles of Clinical Pharmacology course.

Selected Publications

  1. Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KS, Fang Y, Huang XP, Mayo CL, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA Jr, Gould TD. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533(7604):481-6.
  2. Lin GL, Wilson KM, Ceribelli M, Stanton BZ, Woo PJ, Kreimer S, Qin EY, Zhang X, Lennon J, Nagaraja S, Morris PJ, Quezada M, Gillespie SM, Duveau DY, Michalowski AM, Shinn P, Guha R, Ferrer M, Klumpp-Thomas C, Michael S, McKnight C, Minhas P, Itkin Z, Raabe EH, Chen L, Ghanem R, Geraghty AC, Ni L, Andreasson KI, Vitanza NA, Warren KE, Thomas CJ, Monje M. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. Sci Transl Med. 2019;11(519).
  3. Morse DB, Michalowski AM, Ceribelli M, De Jonghe J, Vias M, Riley D, Davies-Hill T, Voss T, Pittaluga S, Muus C, Liu J, Boyle S, Weitz DA, Brenton JD, Buenrostro JD, Knowles TPJ, Thomas CJ. Positional influence on cellular transcriptional identity revealed through spatially segmented single-cell transcriptomics. Cell Syst. 2023;14(6):464-481.e7.
  4. Melani C, Lakhotia R, Pittaluga S, Phelan JD, Huang DW, Wright G, Simard J, Muppidi J, Thomas CJ, Ceribelli M, Tosto FA, Yang Y, Xu W, Davies-Hill T, Pack SD, Peer CJ, Arisa O, Mena E, Lindenberg L, Bergvall E, Portell CA, Farah RJ, Lee ST, Pradhan A, Morrison C, Tadese A, Juanitez AM, Lu C, Jacob A, Simmons H, Figg WD, Steinberg SM, Jaffe ES, Roschewski M, Staudt LM, Wilson WH. Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma. N Engl J Med. 2024;390(23):2143-2155.
  5. Raja SM, Guptill JT, Mack M, Peterson M, Byard S, Twieg R, Jordan L, Rich N, Castledine R, Bourne S, Wilmshurst M, Oxendine S, Avula SGC, Zuleta H, Quigley P, Lawson S, McQuaker SJ, Ahmadkhaniha R, Appelbaum LG, Kowalski K, Barksdale CT, Gufford BT, Awan A, Sancho AR, Moore MC, Berrada K, Cogan GB, DeLaRosa J, Radcliffe J, Pao M, Kennedy M, Lawrence Q, Goldfeder L, Amanfo L, Zanos P, Gilbert JR, Morris PJ, Moaddel R, Gould TD, Zarate CA Jr, Thomas CJ. A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy Volunteers. Clin Pharmacol Ther. 2024.

Related Scientific Focus Areas

This page was last updated on Thursday, October 10, 2024